Purchase Order 75D30120P09178
- Not listed
- Qiagen, LLC has been awarded a $50,809.30 firm fixed price purchase order by the Department of Health and Human Services Centers for Disease Control and Prevention located in Pittsburgh, Pennsylvania. The award is for the delivery of QIACUBE HT/QIAXTRACTOR platforms and reagents to support the agency's biomedical research and public health programs. No set-aside designation was applied to this procurement. Performance will take place in Germantown, Maryland by Qiagen, a division of Qiagen...
- This is a firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of the multinational biotechnology company Qiagen N.V. The $78,929.50 contract is for the provision of laboratory equipment to support the CDC's Division of Digital Public Health and Scientific Information Services (DDPHSIS). The award does not have a set-aside designation. Qiagen is an experienced federal contractor, holding multiple indefinite delivery...
- This firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a division of the international provider of sample and assay technologies Qiagen N.V. The $148,000.00 contract is for the delivery of products and services to support the CDC's biomedical research, public health, and healthcare programs. This includes DNA/RNA extraction kits, next-generation sequencing, digital PCR systems, sample preparation equipment, bioinformatics...
- This firm-fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The $64,817.75 contract provides planned maintenance services for QIAGEN equipment, with a period of performance through March 31, 2024. Qiagen is a major supplier of molecular diagnostics products and services to federal agencies, including the Department of Health and Human Services, Department of Veterans...
- The U.S. Centers for Disease Control and Prevention (CDC) awarded a $79,796.08 firm-fixed-price purchase order to Qiagen, LLC, a division of the international life sciences company Qiagen N.V. The contract is for the purchase of a QIAGEN EZ2 Connect MDX system. This equipment will support the CDC's biomedical research, public health, and healthcare programs. Qiagen has provided a range of laboratory products and services to various federal agencies in the past, including the Department of Health...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $57,348.26 firm fixed-price purchase order contract to Qiagen, LLC, a division of the international provider Qiagen N.V., for QIACUITY equipment and maintenance services. This contract does not have a set-aside designation. Qiagen has a history of providing products and services, such as DNA/RNA extraction kits, next-generation sequencing, and bioinformatics software, to support federal agencies'...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed-price purchase order to Qiagen, LLC, a division of Qiagen N.V., for the acquisition of QIAGEN equipment and reagents. The contract, valued at $134,538.38, does not have a set-aside designation. Qiagen N.V. is an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academic research. The company has a history of supporting federal...
- The U.S. Centers for Disease Control and Prevention (CDC) awarded a $60,250.00 firm fixed price purchase order contract to Qiagen, LLC, a division of the parent company Qiagen N.V. The contract has an ultimate completion date of September 28, 2024 and was awarded on September 29, 2023. Qiagen is an international provider of sample and assay technologies for molecular diagnostics, applied testing, pharmaceuticals, and academics. This contract does not have a set-aside designation. Qiagen has...
- This is a $145,237 firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the multinational biotechnology company Qiagen N.V. The contract is for "other functions" and does not have a set-aside designation. Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, pharma, and academic research. Under this award, Qiagen is likely providing products and services to support the...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $133,979.07 firm fixed price purchase order to Qiagen, LLC, a division of the international life sciences company Qiagen N.V. The contract is for the provision of laboratory equipment and furniture, with a completion date of November 15, 2023. Qiagen is a manufacturer of products and provider of services to support federal agencies' biomedical research, public health, law enforcement, and...
This is a firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Qiagen, LLC, a subsidiary of the Qiagen N.V. biotechnology company. The $113,138.05 contract is for the provision of QIACUBE HT/QIAXTRACTOR platform equipment, which supports the CDC's biomedical research, public health, and healthcare programs. Qiagen is a well-established federal contractor, holding multiple indefinite delivery vehicles (IDVs) and blanket purchase agreements (BPAs) with agencies like the Department of Veterans Affairs, Defense Health Agency, and Federal Bureau of Investigation to provide a range of molecular diagnostics products, reagents, and related services. This award does not have a set-aside designation, reflecting Qiagen's status as a large, international corporation. The contract has an ultimate completion date of August 3, 2022.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Supplemental Agreement for work within scope | ($12k) | 10/30/24 | |
| P00002 | Funding Only Action | ($5) | 12/9/21 | |
| P00001 | Exercise an Option | $11.6k | 6/2/21 | |
| Not listed | Not listed | $101.5k | 8/4/20 |